drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenous bispecific T‑cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells to redirect T cells and induce cytotoxic killing in DLL3‑expressing neuroendocrine cancers.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Obrixtamig (BI 764532) is an intravenous bispecific antibody that binds DLL3 on tumor cells and CD3 on T cells, physically bridging them to activate CD3/TCR signaling and redirect T‑cell cytotoxicity (perforin/granzyme and cytokines) to kill DLL3‑expressing neuroendocrine cancer cells.
drug_name
BI 764532 (obrixtamig)
nct_id_drug_ref
NCT05882058